The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.
 
Richard F. Riedel
Employment - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Leadership - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Stock and Other Ownership Interests - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Consulting or Advisory Role - Daiichi Sankyo; Eisai; GlaxoSmithKline; Ignyta; Lilly; Loxo; Merck; Novartis
Research Funding - AADi (Inst); Agios (Inst); Arog (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Ignyta (Inst); Immune Design (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Plexxikon (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I)
Travel, Accommodations, Expenses - Daiichi Sankyo; EMD Serono; Ignyta; Janssen
 
Karla V. Ballman
Consulting or Advisory Role - ARIAD; Medtronic
Patents, Royalties, Other Intellectual Property - Immune enrichment signature for response to trastuzumab in HER2+ breast cancer (Inst); Prostate cancer signature patent (Inst)
Expert Testimony - Janssen Oncology; Janssen Oncology
 
Yao Lu
No Relationships to Disclose
 
Steven Attia
Research Funding - AB Science (Inst); Bayer (Inst); Bayer (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Dicephera Pharmaceuticals, Inc. (Inst); Epizyme (Inst); Immune Design (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Novartis (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Immune Design
 
Elizabeth Trice Loggers
Research Funding - Daiichi Sankyo (Inst); Epizyme (Inst)
 
Kristen N. Ganjoo
Consulting or Advisory Role - Daiichi Sankyo; Immune Design; Janssen; Novartis
 
Michael B. Livingston
No Relationships to Disclose
 
Warren Allen Chow
Speakers' Bureau - Novartis
Research Funding - Novartis (Inst)
 
Jennifer A. Wright
Employment - Lilly
 
John Harris Ward
No Relationships to Disclose
 
Daniel A. Rushing
Honoraria - Bayer Health; Eisai; Lilly
Consulting or Advisory Role - Bayer Health; Eisai; Lilly
 
Scott H. Okuno
No Relationships to Disclose
 
Damon R. Reed
Consulting or Advisory Role - Janssen Oncology; Loxo; Shire
 
David A. Liebner
Patents, Royalties, Other Intellectual Property - Co-holder of 2 patents ("Methods for Predicting Prognosis") that has been licensed to a private company, MatchTX, LLC.
 
Vicki Leigh Keedy
Employment - Zimmer BioMet (I)
Consulting or Advisory Role - Janssen Oncology; Karyopharm Therapeutics; Threshold Pharmaceuticals
Research Funding - Advenchen Laboratories (Inst); BioMed Valley Discoveries (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); medpacto (Inst); pfizer (Inst); Plexxikon (Inst); Roche (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)
 
Leo Mascarenhas
Honoraria - Bayer
Consulting or Advisory Role - Bayer; Lilly (Inst)
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer; Lilly
 
Lara Emily Davis
Consulting or Advisory Role - Eisai; Immune Design; Loxo
Research Funding - Novartis
 
Christopher W. Ryan
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Novartis; Pfizer
Research Funding - Argos Therapeutics (Inst); Bristol-Myers Squibb (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline/Novartis (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); MabVax (Inst); Merck (Inst); Morphotek (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)
 
Denise K. Reinke
No Relationships to Disclose
 
Robert G. Maki
Honoraria - Lilly; Springer; Wiley
Consulting or Advisory Role - AADi; American Board of Internal Medicine (ABIM); Arcus Ventures; Bayer; Deciphera; Eisai; Immune Design; Karyopharm Therapeutics; Lilly/ImClone; Presage Biosciences; SARC: Sarcoma Alliance for Research though Collaboration; TRACON Pharma
Research Funding - Daiichi Sankyo (Inst); Immune Design (Inst); Immunocore (Inst); Lilly (Inst); Presage Biosciences (Inst); Regeneron (Inst); TRACON Pharma (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Uptodate: I write and edit chapters for their online text book.
Travel, Accommodations, Expenses - TRACON Pharma